Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

Study of the Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis in the West Indies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03832374

Acronym

ACPPPA

Enrollment

Registered

2019-02-06

Start date

2016-06-02

Completion date

2022-03-31

Last updated

2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs. The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways. Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Interventions

OTHERDescriptive

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with rheumatoid arthritis ACR/EULAR 2010 * Patient with a higher age or equal to 18 * Patient receiving social security * Patient giving his free and informed written consent

Exclusion criteria

* Patient with overlap syndrome with another autoimmune disease * Patients with known severe cardiopulmonary pathology * Woman who is pregnant and breast feeding * Patient with language difficulties or understanding

Design outcomes

Primary

Measure	Time frame	Description
Frequency of the positivity of the anti citrullinated peptide antibodies and subtype	three years	Presence of one or more subtypes of anti citrullinated peptide antibodies in the serum of patients with interstitial pneumopathy associated with rheumatoid arthritis who would be absent

Secondary

Measure	Time frame	Description
Genetic analysis of the main mutations	three years	Presence of mutation TERT, RTEL1, PARN et SFTPC

Countries

Martinique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026